Neoadjuvant Therapy With Disitamab Vedotin in Treating Muscle-Invasive Bladder Cancer: A Case Report

This case report presents a 68-year-old man with muscle-invasive bladder cancer (MIBC) and severe renal insufficiency, who was ineligible for cisplatin-based chemotherapy. He was treated with neoadjuvant therapy using gemcitabine and Disitamab Vedotin (DV), resulting in a significant reduction in tumor size and achieving a radiological partial response without significant adverse effects. The patient remained cancer-free during follow-up. This case suggests that gemcitabine and DV could be a viable alternative for cisplatin-ineligible MIBC patients, highlighting the potential of DV, a HER2-targeting antibody-drug conjugate, in treating urothelial carcinoma, even with low or unstable HER2 expression.